Low levels of IgM antibodies against an advanced glycation endproduct-modified apolipoprotein B100 peptide predict cardiovascular events in nondiabetic subjects

Journal of Immunology

Volumn 195, Issue 7, 2015, Pages 3020-3025

  Engelbertsen, Daniel ^a,c   Vallejo, Jenifer ^a   Dan Quách, Tâm ^b   Fredrikson, Gunilla Nordin ^a   Alm, Ragnar ^a   Hedblad, Bo ^a   Björkbacka, Harry ^a   Rothstein, Thomas L ^b   Nilsson, Jan ^a   Bengtsson, Eva ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; IMMUNOGLOBULIN M ANTIBODY; LOW DENSITY LIPOPROTEIN; METHYLGLYOXAL; ANTIBODY; AUTOANTIBODY; CYTOKINE; GLUCOSE BLOOD LEVEL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OXIDIZED LOW DENSITY LIPOPROTEIN;

AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL SELECTION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TH1 CELL; TH2 CELL; ANALYSIS; ATHEROSCLEROSIS; B LYMPHOCYTE; BLOOD; CARDIOVASCULAR DISEASES; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; AUTOANTIBODIES; B-LYMPHOCYTES; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CYTOKINES; DIABETES MELLITUS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEINS, LDL; MALE; PYRUVALDEHYDE; RISK FACTORS;

EID: 84942465581     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402869     Document Type: Article

References (37)

1. Hansson, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695.
2. Hansson, G. K., and A. Hermansson. 2011. The immune system in atherosclerosis. Nat. Immunol. 12: 204-212.
3. Palinski, W., and J. L. Witztum. 2000. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J. Intern. Med. 247: 371-380.
4. Karvonen, J., M. Päivänsalo, Y. A. Kesäniemi, and S. Hörkkö. 2003. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108: 2107-2112.
5. Mayr, M., S. Kiechl, S. Tsimikas, E. Miller, J. Sheldon, J. Willeit, J. L. Witztum, and Q. Xu. 2006. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J. Am. Coll. Cardiol. 47: 2436-2443.
6. Tsimikas, S., E. S. Brilakis, R. J. Lennon, E. R. Miller, J. L. Witztum, J. P. McConnell, K. S. Kornman, and P. B. Berger. 2007. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J. Lipid Res. 48: 425-433.
7. Su, J., A. Georgiades, R. Wu, T. Thulin, U. de Faire, and J. Frostegard. 2006. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188: 160-166.
8. Ravandi, A., S. M. Boekholdt, Z. Mallat, P. J. Talmud, J. J. Kastelein, N. J. Wareham, E. R. Miller, J. Benessiano, A. Tedgui, J. L.Witztum, et al. 2011. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J. Lipid Res. 52: 1829-1836.
9. Binder, C. J. 2012. Naturally occurring IgM antibodies to oxidation-specific epitopes. Adv. Exp. Med. Biol. 750: 2-13.
10. Goldin, A., J. A. Beckman, A. M. Schmidt, and M. A. Creager. 2006. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605.
11. Tames, F. J., M. I. Mackness, S. Arrol, I. Laing, and P. N. Durrington. 1992. Nonenzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 93: 237-244.
12. Virella, G., S. R. Thorpe, N. L. Alderson, M. B. Derrick, C. Chassereau, J. M. Rhett, and M. F. Lopes-Virella. 2004. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J. Lipid Res. 45: 1859-1867.
13. Virella, G., S. R. Thorpe, N. L. Alderson, E. M. Stephan, D. Atchley, F. Wagner, and M. F. Lopes-Virella, DCCT/EDIC Research Group. 2003. Autoimmune response to advanced glycosylation end-products of human LDL. J. Lipid Res. 44: 487-493.
14. Lopes-Virella, M. F., K. J. Hunt, N. L. Baker, J. Lachin, D. M. Nathan, and G. Virella, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. 2011. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 60: 582-589.
15. Lopes-Virella, M. F., M. B. McHenry, S. Lipsitz, E. Yim, P. F. Wilson, D. T. Lackland, T. Lyons, A. J. Jenkins, and G. Virella, DCCT/EDIC Research Group. 2007. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 190: 359-369.
16. Baynes, J. W. 2001. The role of AGEs in aging: causation or correlation. Exp. Gerontol. 36: 1527-1537.
17. Engelbertsen, D., D. V. Anand, G. N. Fredrikson, D. Hopkins, R. Corder, P. K. Shah, A. Lahiri, J. Nilsson, and E. Bengtsson. 2012. High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes. J. Intern. Med. 271: 82-89.
18. Fredrikson, G. N., B. Hedblad, G. Berglund, R. Alm, M. Ares, B. Cercek, K. Y. Chyu, P. K. Shah, and J. Nilsson. 2003. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 872-878.
19. Hedblad, B., P. Nilsson, L. Janzon, and G. Berglund. 2000. Relation between insulin resistance and carotid intima-media thickness and stenosis in nondiabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet. Med. 17: 299-307.
20. Engelbertsen, D., L. Andersson, I. Ljungcrantz, M. Wigren, B. Hedblad, J. Nilsson, and H. Bjorkbacka. 2013. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. Arterioscler. Thromb. Vasc. Biol. 33: 637-644.
21. Wendelhag, I., O. Wiklund, and J. Wikstrand. 1996. On quantifying plaque size and intima-media thickness in carotid and femoral arteries. Comments on results from a prospective ultrasound study in patients with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 16: 843-850.
22. Rosvall, M., L. Janzon, G. Berglund, G. Engström, and B. Hedblad. 2005. Incident coronary events and case fatality in relation to common carotid intimamedia thickness. J. Intern. Med. 257: 430-437.
23. Engström, G., I. Jerntorp, H. Pessah-Rasmussen, B. Hedblad, G. Berglund, and L. Janzon. 2001. Geographic distribution of stroke incidence within an urban population: relations to socioeconomic circumstances and prevalence of cardiovascular risk factors. Stroke 32: 1098-1103.
24. Fredrikson, G. N., B. Hedblad, G. Berglund, R. Alm, J. A. Nilsson, A. Schiopu, P. K. Shah, and J. Nilsson. 2007. Association between IgM against an aldehydemodified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 38: 1495-1500.
25. Sjögren, P., G. N. Fredrikson, A. Samnegard, C. G. Ericsson, J. Ohrvik, R. M. Fisher, J. Nilsson, and A. Hamsten. 2008. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur. Heart J. 29: 2218-2226.
26. Ahmed, M. U., E. Brinkmann Frye, T. P. Degenhardt, S. R. Thorpe, and J. W. Baynes. 1997. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem. J. 324: 565-570.
27. Sämpi, M., O. Ukkola, M. Päivänsalo, Y. A. Kesäniemi, C. J. Binder, and S. Hörkkö. 2008. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. J. Am. Coll. Cardiol. 52: 1370-1378.
28. Binder, C. J., K. Hartvigsen, M. K. Chang, M. Miller, D. Broide, W. Palinski, L. K. Curtiss, M. Corr, and J. L. Witztum. 2004. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114: 427-437.
29. Kyaw, T., C. Tay, S. Krishnamurthi, P. Kanellakis, A. Agrotis, P. Tipping, A. Bobik, and B. H. Toh. 2011. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ. Res. 109: 830-840.
30. Brown, B. E., R. T. Dean, and M. J. Davies. 2005. Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells. Diabetologia 48: 361-369.
31. Brown, B. E., I. Rashid, D. M. van Reyk, and M. J. Davies. 2007. Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocytederived macrophages. FEBS J. 274: 1530-1541.
32. Boullier, A., K. L. Gillotte, S. Hörkkö, S. R. Green, P. Friedman, E. A. Dennis, J. L. Witztum, D. Steinberg, and O. Quehenberger. 2000. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J. Biol. Chem. 275: 9163-9169.
33. Tsimikas, S., A. Miyanohara, K. Hartvigsen, E. Merki, P. X. Shaw, M. Y. Chou, J. Pattison, M. Torzewski, J. Sollors, T. Friedmann, et al. 2011. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J. Am. Coll. Cardiol. 58: 1715-1727.
34. Artwohl, M., W. F. Graier, M. Roden, M. Bischof, A. Freudenthaler, W. Waldhäusl, and S. M. Baumgartner-Parzer. 2003. Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes 52: 1240-1247.
35. Ferretti, G., R. A. Rabini, T. Bacchetti, A. Vignini, E. Salvolini, F. Ravaglia, G. Curatola, and L. Mazzanti. 2002. Glycated low-density lipoproteins modify platelet properties: a compositional and functional study. J. Clin. Endocrinol. Metab. 87: 2180-2184.
36. Zhang, J., S. Ren, D. Sun, and G. X. Shen. 1998. Influence of glycation on LDLinduced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18: 1140-1148.
37. Sun, L., T. Ishida, T. Yasuda, Y. Kojima, T. Honjo, Y. Yamamoto, H. Yamamoto, S. Ishibashi, K. Hirata, and Y. Hayashi. 2009. RAGE mediates oxidized LDLinduced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc. Res. 82: 371-381.